지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.1
- 수록면
- 172 - 180 (9page)
이용수
초록· 키워드
오류제보하기
Despite all these exciting developments, there remain some unmet needs in the management for patients with chronic hepatitis B (CHB). As majority of CHB patients are going to use oral nucleos(t)ide analogues (NAs) for decades, Safety profile of NAs is of no doubt an important issue. The newest nucleotide analogue tenofovir alafenamide is potent in terms of viral suppression, together with favourable renal and bone safety profile. Biochemical response as reflected by alanine aminotransferase (ALT) normalization is recently found to be prognostically important. Patients who achieved ALT normalization have reduced the risk of hepatic events by 49%. Functional cure as reflected by hepatitis B surface antigen seroclearance not only implies patients may stop NA treatment, it also confers to a reduced risk of hepatocellular carcinoma and other hepatic events. Hence functional cure should be the ultimate treatment goal in CHB patients. Preemptive antiviral treatment may reduce mother-to-child transmission of hepatitis B virus, especially if birth dose of vaccination cannot be given in the first two hours after delivery. Lastly, despite the currently first-line NAs have highgenetic barrier to drug resistance mutations, there are still are many patients who were previously treated with low barrier of resistance including lamivudine, telbivudine or adefovir dipivoxil which could lead to antiviral resistance and affecting the choice of NAs.
목차
등록된 정보가 없습니다.
참고문헌 (52)
참고문헌 신청
World Health Organization / Hepatitis B Fact Sheet N204:Hepatitis B
Chan SL / 2016 / Infection and cancer : the case of hepatitis B / J Clin Oncol 34:83~90
Liu K / 2017 / Tenofovir treatment reduces hepatocellular carcinoma and deaths in chronic hepatitis B patients with liver cirrhosis / Hepatol Int 11(Suppl 1):S84
Wong GL / 2013 / Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis / Hepatology 58:1537~1547
Lok AS / 2017 / Hepatitis B cure : from discovery to regulatory approval / Hepatology 66:1296~1313
Chan SL / 2016 / Infection and cancer : the case of hepatitis B / J Clin Oncol 34:83~90
Liu K / 2017 / Tenofovir treatment reduces hepatocellular carcinoma and deaths in chronic hepatitis B patients with liver cirrhosis / Hepatol Int 11(Suppl 1):S84
Wong GL / 2013 / Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis / Hepatology 58:1537~1547
Lok AS / 2017 / Hepatitis B cure : from discovery to regulatory approval / Hepatology 66:1296~1313
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Another oral antiviral treatment, but still far away from hepatitis B virus cure
Clinical and Molecular Hepatology
2021 .01
-
Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers
Clinical and Molecular Hepatology
2023 .01
-
Predictive Value of Antiviral Effects in the Development of Hepatocellular Carcinoma in the General Korean Population with Chronic Hepatitis B
Gut and Liver
2016 .01
-
Quantitative Hepatitis B Surface Antigen, the Trustworthy Biomarker for Functional Cure of Chronic Hepatitis B
Gut and Liver
2023 .03
-
Current and future strategies for the treatment of chronic hepatitis C
Clinical and Molecular Hepatology
2021 .01
-
Hepatitis C Virus and Antiviral Drug Resistance
Gut and Liver
2016 .01
-
국내 만성 B형 간염 환자의 경구용 항바이러스제 사용 현황 분석
한국임상약학회지
2016 .01
-
Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
Gut and Liver
2021 .01
-
Hepatitis C Virus Associated Hepatocellular Carcinoma Risk
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)
Clinical and Molecular Hepatology
2016 .01
-
A Program to Treat Hepatitis B in North Korea: A Model of Antiviral Therapy in a Resource-Poor Setting
Gut and Liver
2018 .01
-
The role of different viral biomarkers on the management of chronic hepatitis B
Clinical and Molecular Hepatology
2023 .04
-
만성 B형 간염 환자에서 아데포비어 사용 중 발생한 골절을 동반한골연화증 3예
OSTEOPOROSIS
2015 .01
-
Management of Antiviral Resistance in Chronic Hepatitis B
Gut and Liver
2017 .01
-
Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?
Clinical and Molecular Hepatology
2021 .01
-
Overview of anti-Hepatitis B virus agents
JOURNAL OF BACTERIOLOGY AND VIROLOGY
2020 .09
-
Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)idenaïve patients
Clinical and Molecular Hepatology
2017 .01
-
만성 B형 간염 소아청소년 환자에서의 라미부딘 치료 효과
Pediatric Infection and Vaccine
2018 .01
-
Long-term surgical outcomes of liver resection for hepatocellular carcinoma in patients with hepatitis B virus and hepatitis C virus co-infection: A multicenter observational study
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .12
-
Drug-drug interactions with direct-acting antivirals ? less is more
Clinical and Molecular Hepatology
2021 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0